
UnitedHealth Group Incorporated

UNH (UnitedHealth Group Incorporated) trades at 0.7x EV/Revenue — attractively valued for a healthcare & pharma company with thin margins (19%) and mature growth profile. The business is approaching profitability at 5% EBIT margins. Forward PE of 15x.
The average bear market lasts 9.6 months with a 36% decline. The average bull market lasts 2.7 years with a 114% gain.
UnitedHealth Group is America's largest healthcare company, operating as both a health insurer (covering 53+ million Americans) and a healthcare services provider. They make money through insurance premiums, government contracts (Medicare/Medicaid), and by owning one of the largest networks of doctors, clinics, and pharmacies in the country. Think of them as the Amazon of healthcare — they control multiple layers of the healthcare value chain.
UNH has delivered 13%+ annual revenue growth over the past decade, driven by Medicare Advantage membership expansion and Optum's healthcare services acquisitions. The company targets $100+ billion in Optum revenue by 2025, representing massive growth from current levels. With 10,000 Americans turning 65 daily and increasing preference for MA plans over traditional Medicare, the demographic runway extends well into the 2030s.
UNH maintains best-in-class operating margins around 8-9% with strong free cash flow generation exceeding $20+ billion annually. The Optum services division operates at higher margins than traditional insurance, driving overall margin expansion as it grows to represent 40%+ of total revenue. Their diversified model provides earnings stability even during challenging medical cost environments.
UNH dominates with 30%+ market share in Medicare Advantage and is the clear leader in healthcare services through Optum. Key competitors include Anthem, Aetna (CVS), and Humana, but none match UNH's scale and vertical integration. Their data advantage from millions of patient interactions creates a significant moat for care management and cost prediction.
*Note: Specific recent quarter data unavailable, but UNH typically reports steady performance with medical loss ratios in target ranges and continued Optum growth acceleration.* The company has historically beaten earnings expectations consistently and maintained strong forward guidance. Market reaction tends to be positive on strong membership growth and Optum expansion updates.
UNH is widely considered a defensive growth stock with most analysts maintaining Buy ratings and price targets reflecting continued premium valuations. The main debate centers on regulatory risk versus growth sustainability, with bulls emphasizing the demographic opportunity and bears worried about government intervention. Consensus expects high-single to low-double digit earnings growth.
UNH is the closest thing to a "must-own" stock in healthcare — a diversified giant riding unstoppable demographic trends with multiple ways to win, though regulatory risks require monitoring.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $441.4B | $454.2B | $481.5B |
| Growth | — | +3% | +6% | |
| EBITDA | — | $36.4B | $37.4B | $39.7B |
| Growth | — | +3% | +6% | |
| EPS (PF) | — | $17.85 | $19.80 | $23.78 |
| Growth | — |
Goldman Sachs Large Cap Value Fund: Q4 2025 Portfolio Attribution And Review
UnitedHealth, Hims & Hers, Gambling.Com - Value Investing With Raul Shah
UnitedHealth Group Announces Earnings Release Date
UnitedHealth: Stabilizing, But Not Yet A Buy
UnitedHealth Group: Still A Generational Buying Opportunity
| +11% |
| +20% |